[
  {
    "ts": "2025-11-20T00:21:13+00:00",
    "headline": "Why Exact Sciences Stock Blasted Nearly 24% Higher Today",
    "summary": "A strategic investor is reportedly in advanced talks to purchase the company.",
    "url": "https://www.fool.com/investing/2025/11/19/why-exact-sciences-stock-blasted-nearly-24-higher/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "e97b778c-2765-3761-a2a4-57ecf297f9a8",
      "content": {
        "id": "e97b778c-2765-3761-a2a4-57ecf297f9a8",
        "contentType": "STORY",
        "title": "Why Exact Sciences Stock Blasted Nearly 24% Higher Today",
        "description": "",
        "summary": "A strategic investor is reportedly in advanced talks to purchase the company.",
        "pubDate": "2025-11-20T00:21:13Z",
        "displayTime": "2025-11-20T00:21:13Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/3f38c292862ad0436ec6e7612c8c65a2",
          "originalWidth": 1400,
          "originalHeight": 683,
          "caption": "Person in a lab gazing into a microscope.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/5QpJoH9EvdmMb5M539dGLg--~B/aD02ODM7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/3f38c292862ad0436ec6e7612c8c65a2.cf.webp",
              "width": 1400,
              "height": 683,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/lkNZnqaCSaCOQB91IHF8bA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/3f38c292862ad0436ec6e7612c8c65a2.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2025/11/19/why-exact-sciences-stock-blasted-nearly-24-higher/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/why-exact-sciences-stock-blasted-002113886.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "EXAS"
            },
            {
              "symbol": "ABT"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-20T10:51:00+00:00",
    "headline": "Diabetes Care Devices Markets, 2023-2024 & 2025-2033 with Abbott, Dexcom, Medtronic, Roche, Ascensia, LifeScan, Novo Nordisk, Eli Lilly, and Sanofi Leading",
    "summary": "The diabetes care devices market is driven by rising diabetes cases and demand for advanced monitoring and insulin solutions. Opportunities lie in emerging markets where lifestyle shifts increase diabetes rates, along with innovations like AI analytics and connected devices accelerating personalized care.Dublin, Nov. 20, 2025 (GLOBE NEWSWIRE) -- The \"Diabetes Care Devices Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and For",
    "url": "https://finance.yahoo.com/news/diabetes-care-devices-markets-2023-105100577.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "1eaab3e8-e087-3caa-b8a7-b976eb03ea7f",
      "content": {
        "id": "1eaab3e8-e087-3caa-b8a7-b976eb03ea7f",
        "contentType": "STORY",
        "title": "Diabetes Care Devices Markets, 2023-2024 & 2025-2033 with Abbott, Dexcom, Medtronic, Roche, Ascensia, LifeScan, Novo Nordisk, Eli Lilly, and Sanofi Leading",
        "description": "",
        "summary": "The diabetes care devices market is driven by rising diabetes cases and demand for advanced monitoring and insulin solutions. Opportunities lie in emerging markets where lifestyle shifts increase diabetes rates, along with innovations like AI analytics and connected devices accelerating personalized care.Dublin, Nov. 20, 2025 (GLOBE NEWSWIRE) -- The \"Diabetes Care Devices Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and For",
        "pubDate": "2025-11-20T10:51:00Z",
        "displayTime": "2025-11-20T10:51:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc",
          "originalWidth": 480,
          "originalHeight": 58,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/_MlAqEncKPaKK77zrkRGmQ--~B/aD01ODt3PTQ4MDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc.cf.webp",
              "width": 480,
              "height": 58,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/caWFqk489OEmv3xI33JamQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/diabetes-care-devices-markets-2023-105100577.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/diabetes-care-devices-markets-2023-105100577.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ABT"
            },
            {
              "symbol": "DXCM"
            },
            {
              "symbol": "MDT"
            },
            {
              "symbol": "ROG.SW"
            },
            {
              "symbol": "NOVO-B.CO"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-20T12:30:00+00:00",
    "headline": "Abbott to acquire Exact Sciences, a leader in large and fast-growing cancer screening and precision oncology diagnostics segments",
    "summary": "Abbott (NYSE: ABT) and Exact Sciences (NASDAQ: EXAS) today announced a definitive agreement for Abbott to acquire Exact Sciences, which will enable it to enter and lead in fast-growing cancer diagnostics segments, serving millions more people. Under the terms of the agreement, Exact Sciences shareholders will receive $105 per common share, representing a total equity value of approximately $21 billion.",
    "url": "https://finance.yahoo.com/news/abbott-acquire-exact-sciences-leader-123000022.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "5a997942-5bf7-39d5-bff3-8950de1cacf2",
      "content": {
        "id": "5a997942-5bf7-39d5-bff3-8950de1cacf2",
        "contentType": "STORY",
        "title": "Abbott to acquire Exact Sciences, a leader in large and fast-growing cancer screening and precision oncology diagnostics segments",
        "description": "",
        "summary": "Abbott (NYSE: ABT) and Exact Sciences (NASDAQ: EXAS) today announced a definitive agreement for Abbott to acquire Exact Sciences, which will enable it to enter and lead in fast-growing cancer diagnostics segments, serving millions more people. Under the terms of the agreement, Exact Sciences shareholders will receive $105 per common share, representing a total equity value of approximately $21 billion.",
        "pubDate": "2025-11-20T12:30:00Z",
        "displayTime": "2025-11-20T12:30:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/f534f52fc139a00af7e0b83803fad1e0",
          "originalWidth": 16,
          "originalHeight": 16,
          "caption": "Cision",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/LGZcG5ViJsTwelyQu1wmXw--~B/aD0xNjt3PTE2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/f534f52fc139a00af7e0b83803fad1e0.cf.webp",
              "width": 16,
              "height": 16,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/lAY7E2WBIPHdmYniwW.kjg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/f534f52fc139a00af7e0b83803fad1e0.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/abbott-acquire-exact-sciences-leader-123000022.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/abbott-acquire-exact-sciences-leader-123000022.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ABT"
            },
            {
              "symbol": "EXAS"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-20T11:27:15+00:00",
    "headline": "Exact Sciences (EXAS) Climbs to 2-Year High on Abbot Merger Reports",
    "summary": "We recently published 10 Stocks Beating Wall Street at its Own Game. Exact Sciences Corp. (NASDAQ:EXAS) is one of the best-performing stocks on Wednesday. Exact Sciences climbed to a new two-year high on Wednesday, as investors loaded portfolios following reports that it set to be taken over by Abbott Laboratories in what could be its […]",
    "url": "https://finance.yahoo.com/news/exact-sciences-exas-climbs-2-112715248.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "efef92df-bdd6-350e-962a-8b07f82b3340",
      "content": {
        "id": "efef92df-bdd6-350e-962a-8b07f82b3340",
        "contentType": "STORY",
        "title": "Exact Sciences (EXAS) Climbs to 2-Year High on Abbot Merger Reports",
        "description": "",
        "summary": "We recently published 10 Stocks Beating Wall Street at its Own Game. Exact Sciences Corp. (NASDAQ:EXAS) is one of the best-performing stocks on Wednesday. Exact Sciences climbed to a new two-year high on Wednesday, as investors loaded portfolios following reports that it set to be taken over by Abbott Laboratories in what could be its […]",
        "pubDate": "2025-11-20T11:27:15Z",
        "displayTime": "2025-11-20T11:27:15Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/b5dad9919dcf999502a6a0d2fc5a1f43",
          "originalWidth": 1000,
          "originalHeight": 667,
          "caption": "Guggenheim Reaffirms Buy on GeneDx, Lifts Price Target to $170 After Q3 Beat",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/jlSXk2cfZ4LwsZmEizTJog--~B/aD02Njc7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/b5dad9919dcf999502a6a0d2fc5a1f43.cf.webp",
              "width": 1000,
              "height": 667,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/GFu55GtTL41F2Sa4eWKtSw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/b5dad9919dcf999502a6a0d2fc5a1f43.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/exact-sciences-exas-climbs-2-112715248.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/exact-sciences-exas-climbs-2-112715248.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "EXAS"
            },
            {
              "symbol": "ABT"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]